{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-24-000033","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2024-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.762623+00:00","generated_at":"2026-05-30T21:29:43.715363+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"AbbVie cuts 2024 adjusted EPS guidance by $0.04 on $82M Q3 IPR&D charge","bullets":["Q3 2024 acquired IPR&D & milestones expense of $82M pre-tax, reducing GAAP and adjusted EPS by $0.04.","Q3 2024 adjusted diluted EPS guidance range now $2.88–$2.92, including the charge.","Full-year 2024 adjusted diluted EPS guidance revised to $10.67–$10.87 from $10.71–$10.91.","Guidance excludes any IPR&D expense beyond Q3 2024 due to forecasting uncertainty.","Q3 2024 results are preliminary and subject to final closing procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-24-000033","json":"https://secwatch.observer/filing/0001551152-24-000033.json","markdown":"https://secwatch.observer/filing/0001551152-24-000033.md","text":"https://secwatch.observer/filing/0001551152-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000033/0001551152-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000033/abbv-20241003.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T21:29:43.715363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}